Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23129641 | 0.98 | LMNA (0.57) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL1672623 | 0.97 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL25381860 | 0.92 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL12987175 | 0.89 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL696997 | 0.89 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL3117465 | 0.89 | ALDH1A1 (0.52) | LMNASLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL6895798 | 0.89 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL6032436 | 0.89 | LMNA (0.53) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL1444506 | 0.87 | LMNA (0.43) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL698390 | 0.87 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164043-A | Compositions and methods for glaucoma | 奥夫博医疗创新有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-8871965-B2 | Method for producing urethanes | BASF SE (DE) | 2014-10-28 | — | — | US | claimed |
| EP-2491011-A1 | METHOD FOR PRODUCING URETHANES | BASF SE (DE) | 2012-08-29 | — | — | EP | claimed |
| US-20120203022-A1 | METHOD FOR PRODUCING URETHANES | BASF SE (DE) | 2012-08-09 | — | — | US | claimed |
| WO-2011048124-A1 | METHOD FOR PRODUCING URETHANES | BASF SE (DE) | 2011-04-28 | — | — | WO | claimed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20030195245-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | BIOTEST LABORATORIES, LLC | 2003-10-16 | — | — | US | disclosed |
| US-20030134830-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
| US-20030134831-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-0315334-B1 | PROCESS FOR THE PREPARATION OF DIANHYDROSORBITOL ETHERS | ICI AMERICAS INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| US-5100872-A | Norbornene carbonates, cosmsetics, detergents | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-5098886-A | Mixing compounds to improve odor | INTERNATIONAL FLAVORS & FRAGRANCES INC., A CORP. OF NEW YORK | 1992-03-24 | — | — | US | disclosed |
| EP-0315334-A2 | Process for the preparation of dianhydrosorbitol ethers | ICI AMERICAS INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4770871-A | DENTIFRICE, ETHERIFICATION | ICI AMERICAS INC. (US) | 1988-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-20030195245-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | CYP2A7, CYP8B1, CYP3A7 | LMNA 147/4885SLC1A3 2438/4885SLC1A2 3103/4885 |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | LMNA 796/4885SLC1A3 4232/4885SLC1A2 4453/4885 |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | TYMP, PNP, SAMHD1 | LMNA 509/4885SLC1A3 1627/4885SLC1A2 1824/4885 |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.